229 related articles for article (PubMed ID: 27015909)
21. Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.
Bolin BL; Stoops WW; Sites JP; Rush CR
J Addict Med; 2016; 10(3):156-65. PubMed ID: 26933876
[TBL] [Abstract][Full Text] [Related]
22. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
23. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.
Mooney ME; Herin DV; Schmitz JM; Moukaddam N; Green CE; Grabowski J
Drug Alcohol Depend; 2009 Apr; 101(1-2):34-41. PubMed ID: 19058926
[TBL] [Abstract][Full Text] [Related]
24. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial.
Falcato L; Beck T; Reimer J; Verthein U
J Clin Psychopharmacol; 2015 Apr; 35(2):150-7. PubMed ID: 25679130
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of interim methadone maintenance.
Schwartz RP; Highfield DA; Jaffe JH; Brady JV; Butler CB; Rouse CO; Callaman JM; O'Grady KE; Battjes RJ
Arch Gen Psychiatry; 2006 Jan; 63(1):102-9. PubMed ID: 16389204
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
27. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial.
Baldaçara L; Cogo-Moreira H; Parreira BL; Diniz TA; Milhomem JJ; Fernandes CC; Lacerda AL
J Clin Psychiatry; 2016 Mar; 77(3):398-406. PubMed ID: 27046312
[TBL] [Abstract][Full Text] [Related]
29. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
Rush CR; Stoops WW; Hays LR
Drug Alcohol Depend; 2009 Jan; 99(1-3):261-71. PubMed ID: 18926645
[TBL] [Abstract][Full Text] [Related]
30. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
31. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
32. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
34. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
[TBL] [Abstract][Full Text] [Related]
35. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial.
Grabowski J; Rhoades H; Schmitz J; Stotts A; Daruzska LA; Creson D; Moeller FG
J Clin Psychopharmacol; 2001 Oct; 21(5):522-6. PubMed ID: 11593078
[TBL] [Abstract][Full Text] [Related]
36. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of double-blind clinical trials with oral diacetylmorphine: a randomized controlled phase II study in an inpatient setting.
Colom Farran J; Casas M; Pérez de Los Cobos J; Del Río M; Roncero C; Castells X; Valero S; Eiroa-Orosa FJ; Batlle F; Trujols J
Eur Addict Res; 2012; 18(6):279-87. PubMed ID: 22854605
[TBL] [Abstract][Full Text] [Related]
38. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
Allen SJ; Wareham K; Wang D; Bradley C; Hutchings H; Harris W; Dhar A; Brown H; Foden A; Gravenor MB; Mack D
Lancet; 2013 Oct; 382(9900):1249-57. PubMed ID: 23932219
[TBL] [Abstract][Full Text] [Related]
39. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
40. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.
Shearer J; Wodak A; van Beek I; Mattick RP; Lewis J
Addiction; 2003 Aug; 98(8):1137-41. PubMed ID: 12873248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
